Publications by authors named "J F Dahlerup"
Background And Aims: Patients with inflammatory bowel disease (IBD) have lower health-related quality of life (HRQoL) than the general population. The highest incidence and prevalence rates of IBD in the world are found in the Faroe Islands, however, the HRQoL of Faroese patients is unknown. This study aimed to determine their HRQoL at diagnosis and two years of follow-up in comparison with Danish patients.
View Article and Find Full Text PDFBackground And Aims: Chronic fatigue is common in patients with inflammatory bowel disease (IBD). The gut microbiota, specifically, microbial diversity and butyrate-producing bacteria have been linked to the fatigue pathogenesis. High-dose oral thiamine reduces fatigue, potentially through gut microbiota modification.
View Article and Find Full Text PDFArticle Synopsis
- The incidence of inflammatory bowel disease (IBD) in the Faroe Islands has significantly increased over the last 60 years, raising concerns about environmental factors and genetic susceptibilities.
- This study compared environmental factors between Faroese IBD patients and a Danish cohort, analyzing data from 2010 to 2022.
- Findings revealed that Faroese patients had higher rates of specific vaccinations and childhood infections, different dietary habits, and variations in smoking behaviors compared to Danish patients.
Microfibrillar-associated protein 4 as a predictive biomarker of treatment response in patients with chronic inflammatory diseases initiating biologics: secondary analyses based on the prospective BELIEVE cohort study.
Rheumatol Int
December 2024
Background: Currently, there are no reliable biomarkers for predicting treatment response in chronic inflammatory diseases (CIDs).
Objective: To determine whether serum microfibrillar-associated protein 4 (MFAP4) levels can predict the treatment response to biological therapy in patients with CIDs.
Methods: The BELIEVE study was originally designed as a prospective, multi-center cohort study of 233 patients with either rheumatoid arthritis, psoriatic arthritis, psoriasis, axial spondyloarthritis, Crohn's disease, or ulcerative colitis, initiating treatment with a biologic agent (or switching to another).
Background: Faecal microbiota transplantation (FMT) is a highly effective treatment for infection. Its use is backed by solid evidence, but application methods differ. Encapsulated FMT is a non-invasive, patient-friendly and scalable application method that may be preferred over colonoscopy or nasoduodenal tube application.
View Article and Find Full Text PDF